e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Pulmonary hypertension II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS)
P. Blin, K. Bouillon, L. Abenhaim, N. Galie (Paris, France; Bologna, Italy)
Source:
Annual Congress 2008 - Pulmonary hypertension II
Session:
Pulmonary hypertension II
Session type:
Thematic Poster Session
Number:
1032
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Blin, K. Bouillon, L. Abenhaim, N. Galie (Paris, France; Bologna, Italy). Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS). Eur Respir J 2008; 32: Suppl. 52, 1032
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Exercise tolerability in children with pulmonary arterial hypertension (PAH), a population pk/pd assessment of the effects of sildenafil
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety.
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019
Early diagnostic evaluation of pulmonary hypertension in severe COPD patients (preliminary results)
Source: Eur Respir J 2006; 28: Suppl. 50, 657s
Year: 2006
Impact of initiation of sildenafil on patterns of healthcare utilization and cost in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017
Year: 2017
Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept